Search company, investor...

Predict your next investment

Corporation
HEALTHCARE | Biotechnology
nanocarrier.co.jp

Investments

2

Partners & Customers

2

About Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

Headquarters Location

Japan

Want to inform investors similar to Nano Carrier about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Nano Carrier News

New Jetson NANO Carrier, Aetina AN110 Enlighten Edge AIoT Applications Showcased in Embedded World 2020

Feb 14, 2020

New Jetson NANO Carrier, Aetina AN110 Enlighten Edge AIoT Applications Showcased in Embedded World 2020 Small Form Factor, Abundant I/O Support, 4K Camera Extension Offering News provided by Share this article TAIPEI, Feb. 14, 2020 /PRNewswire/ -- As the speedy development of artificial intelligence, the applications have largely expended to all industries. With the results, AI processors have significantly announced to the market. However, to live up the requests from the market, GPGPU and edge computing solutions provider Aetina Corporation provides various alternative products and AI computing platforms for developers' choices. The sparkle carrier this time, Aetina is exciting to demonstrate in Embedded World 2020 at the booth, is the exclusive carrier board AN110 for Jetson Nano module. Potent computing power with low power consumption, and the outlook of small form factor, AN110 platform have ready to show off its AI energies to all nowadays. Aetina carrier board AN110 exclusive for Nvidia Jetson Nano module. Aetina AN110 is an exquisite carrier board for the Nvidia Jetson Nano module, which ignites the AI potential by delivering 472 GFLOPS computing performance and operate as low as 5W. Meanwhile, as the smallest intelligent platform for the Nvidia series, Aetina AN110 is only the size of 87 x 67 mm, will right for the application and ideal for community uses. The edge devices in this generation, have required the ability with intelligent purposes, with AN110, this platform will be equipped multiple I/O with 1x HDMI Type A, 1x RJ-45 for GbE, 2x USB3.2 Gen1 Type-A, 5x GPIO and 1x DC-in 12V. Moreover, AN110 supported 1x 4K or 1x FHD camera for machine vision requirements. Not only for vision-critical AI, but the AN110-Nano platform took a vital role by acting as an intellectual gateway, bring communities to AI functional. Followed Aetina's business vision, the announcement of AN110 combined with Jetson Nano is one of the crucial steps in Aetina's edge AIoT ecosystem blueprint. Add-on Aetina customization and well-experienced service, this platform could be the perfect choice with size features and budget tools. AN110 platform should help to enlighten the intelligent life in the city, and the embedded AI computing platform into edge devices to get closer to AIoT. Aetina founded in Taiwan, as a high-performance GPGPU and Jetson edge AI computing solutions provider of AIoT market, helping customers by offering smart, innovated, and reliable solutions of GPGPU. AN110-Jetson Nano platform will display in Embedded World 2020 at #1-207 booth. Welcome to visit the booth and www.aetina.com to get more details. SOURCE Aetina Corporation

Nano Carrier Investments

2 Investments

Nano Carrier has made 2 investments. Their latest investment was in AccuRna as part of their Series B on January 1, 2018.

CBI Logo

Nano Carrier Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/17/2018

Series B

AccuRna

$4.69M

No

3

3/18/2016

Series A

Subscribe to see more

Subscribe to see more

0

Date

1/17/2018

3/18/2016

Round

Series B

Series A

Company

AccuRna

Subscribe to see more

Amount

$4.69M

New?

No

Subscribe to see more

Co-Investors

Sources

3

0

Nano Carrier Partners & Customers

2 Partners and customers

Nano Carrier has 2 strategic partners and customers. Nano Carrier recently partnered with VBL Therapeutics on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/6/2017

Licensor

Israel

VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan

In addition to this agreement , VBL Therapeutics and NanoCarrier intend to explore future collaborations in oncology .

2

10/31/2007

Licensee

Switzerland

Subscribe to see more

Subscribe to see more

10

Date

11/6/2017

10/31/2007

Type

Licensor

Licensee

Business Partner

Country

Israel

Switzerland

News Snippet

VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan

In addition to this agreement , VBL Therapeutics and NanoCarrier intend to explore future collaborations in oncology .

Subscribe to see more

Subscribe to see more

Sources

2

10

Nano Carrier Team

1 Team Member

Nano Carrier has 1 team member, including current Chief Executive Officer, President, Ichiro Nakatomi.

Name

Work History

Title

Status

Ichiro Nakatomi

Chief Executive Officer, President

Current

Name

Ichiro Nakatomi

Work History

Title

Chief Executive Officer, President

Status

Current

Compare Nano Carrier to Competitors

A
AutekBio

AutekBio is a biotech firm headquartered in the Bay Area, US.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

A
Affibody

Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

P
Pivotal Biosciences

Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.